“There’s no better place to meet our industry partners in person and get a first-hand feel for the state of the pharma industry than at CPHI,” says Borderless Partner Rosalie Harrison, who leads the firm’s life sciences practice. The event in Milan is a unique opportunity to meet our network of business partners, clients, and executives and catch up on the latest developments in the sector.
“I am looking forward to being present at CPHI on October 8 and 9. I hope to meet you if you are attending. Let’s plan a moment to share a coffee using this link.”
“See you in Milan!”
Rosalie can be reached at rosalie.harrison@borderless.net and +32 470 993061.
Lotte Fine Chemical announced on Oct. 7 that it has entered into a global distribution agreement with Colorcon, the world’s leading distributor of pharmaceutical cellulose based in the USA. The agreement, valued at $1 billion, entails the sale of Lotte Fine Chemical’s high-value specialty pharmaceutical cellulose products through Colorcon in the global pharmaceutical market for the next 10 years.
Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for inflammatory diseases.
With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private equity outfit Clayton, Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in its consumer health business, dubbed Opella, the company said Friday.
